Lamivudine in prevention and treatment of recurrent HBV after liver transplantation

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 4, 2004, Pages 504-507

  Lu, Yi ^a   Wang, Bo ^a   Yu, Liang ^a   Liu, Chang ^a   Wu, Zheng ^a   Pan, Cheng En ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Liver transplantation

Indexed keywords

CYCLOSPORIN; HEPATITIS B ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; VIRUS DNA;

ADULT; AGED; ARTICLE; ARTIFICIAL LIVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL CARE; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATION; RECURRENT INFECTION; SURGICAL MORTALITY; TREATMENT OUTCOME; VIREMIA;

ADULT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 9444285503     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003;75:41-44.
2. Liu H, Liu YF. Liver transplantation for patients with viral hepatitis. Hepatobiliary Pancreat Dis Int 2003;2:28-31.
3. Todo S, Denetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for paitients with hepatitis B virus-related disease. Hepatology 1991;13:619-626.
4. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997;63:393-396.
5. Herrero JI, Quiroga J, Sangro B, Sola I, Riezu-Boj JI, Pardo F. Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Dig Dis Sci 1998; 43: 1186-1189.
6. Jurim O, Martin P, Shaked A, Goldstein L, Millis JM, Calquhoun SD, et al. Liver transplantation for chronic hepatitis B in Asians. Transplantation 1994;57:1393-1395.
7. Lee HC, Suh DJ. Lamivudine therapy for decompensated liver cirrhosis related to hepatitis B virus infection. Intervirology 2003;46:388-393.
8. Hanazaki K. Antiviral therapy for chronic hepatitis B: a review. Curr Drug Targets Inflamm Allergy 2004;3:63-70.
9. I. Alonso, A, Herreros de Tejada A, Moreno JM, Rubio E, Lucena JL, De la Revilla J. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. Transplant Proc 2003;35:1850-1851.
10. Golling M, Arnold JC, Rudek B, Mehrabi A, Kraus T, Herfarth C. HBV prophylaxis: Cost/benefit analysis following liver transplantation for HBV-posidve liver cirrhosis. Transplant Proc 1998;30:3316-3317.
11. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP. Liver transplantation in European patients with hepatic B surface antigen. N Engl J Med 1993;329:1842-1847.
12. Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 2000;32:1189-1195.
13. Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 2003;7: 537-550.
14. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD. Efficacy of lamivudine in patients with hepatitis Be antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-896.
15. Cho SW, Hahm Ki-B, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1163-1169.
16. Zoulim F, Trepo C. Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 2000; 32: 1172-1174.
17. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003;37:27-35.
18. Zheng SS, Wu J, Liang TB, Wang WL, Huang DS, Xu X. Prohphylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int 2002;1:327-329.
19. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
20. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003;51: 761-785.
21. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G. Lamivudine without HBIg for the prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809-815.
22. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003;3:999-1002.
23. Albeniz AE, Barcena MR, Oton NE, Mateo LM, Garcia GM, de Vicente LE. Use of combined treatment of hepatitis B immune globulin and lamivudine as prevention of hepatitis B virus recurrence in liver allograft. Transplant Proc 2003;35:1844-1855.
24. Lu SC, Yan LN, Li B, Wen TF, Zhao JC, Cheng NS. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation. Hepatobiliary Pancreat Dis Int 2004;3:26-32.
25. Zhu JP, Zhang TL, Li L, Yuan J, Song SB, Xiu DR. Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2003;2:500-503.
26. Beckebaum S, Cicinnati VR, Gerken G, Broelsch CE. Treatment of hepatitis B reinfection after liver transplantation. Minerva Chir 2003;58:705-716.
27. Perrilo R, Wright T, Rakela J, Levy G, Schiff E, Gish R. A multicenter united tated-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.
28. Nery JR, Weppler D, Lavandera R, Nery AC, Magill A, Rodriguez M. Developing strategies for prevention and treatment of recurrent HBV in liver transplantation. Transplant Proc 1999;31:485-486.
29. Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39: 850-855.
30. Zhou DY, Cao YJ, Lin LY, Wang H, Huang JS. HBV resistant to lamivudine: experimental and clinical studies. Hepatobiliary Pancreat Dis Int 2002;1:519-522.
31. Zhou DY, Lin LY, Wang H, Huang JS . The relationship between HBV lamivudine resistance and HBV genotypes or basic coreomoter mutations. Hepatobiliary Pancreat Dis Int 2003;2: 85-89.
32. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
33. Loeb KR, Jerome KR, Goddard J, Huang MI, Cent A, Corey L. High throughout quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000;32:626-629.
34. Toniutto P, Fumo E, Caldato M, Apollonio L, Perin A, Pirisi M. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004;77:472-473.
35. Wiegand J, Tischendorf JJ, Nashan B, Klempnauer J, Flemming P, Niemann P. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Z Gastroenterol 2004;42:15-18.